Serum Autotaxin Is a Useful Disease Progression Marker in Patients with Primary Biliary Cholangitis
Abstract Autotaxin (ATX) is a secreted enzyme metabolized by liver sinusoidal endothelial cells that has been associated with liver fibrosis. We evaluated serum ATX values in 128 treatment-naïve, histologically assessed primary biliary cholangitis (PBC) patients and 80 healthy controls for compariso...
Guardado en:
| Autores principales: | , , , , , , , , , , , , , |
|---|---|
| Formato: | article |
| Lenguaje: | EN |
| Publicado: |
Nature Portfolio
2018
|
| Materias: | |
| Acceso en línea: | https://doaj.org/article/715988f2566c47be81b9f75420628d74 |
| Etiquetas: |
Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!
|
| id |
oai:doaj.org-article:715988f2566c47be81b9f75420628d74 |
|---|---|
| record_format |
dspace |
| spelling |
oai:doaj.org-article:715988f2566c47be81b9f75420628d742021-12-02T15:08:19ZSerum Autotaxin Is a Useful Disease Progression Marker in Patients with Primary Biliary Cholangitis10.1038/s41598-018-26531-02045-2322https://doaj.org/article/715988f2566c47be81b9f75420628d742018-05-01T00:00:00Zhttps://doi.org/10.1038/s41598-018-26531-0https://doaj.org/toc/2045-2322Abstract Autotaxin (ATX) is a secreted enzyme metabolized by liver sinusoidal endothelial cells that has been associated with liver fibrosis. We evaluated serum ATX values in 128 treatment-naïve, histologically assessed primary biliary cholangitis (PBC) patients and 80 healthy controls for comparisons of clinical parameters in a case-control study. The median ATX concentrations in controls and PBC patients of Nakanuma’s stage I, II, III, and IV were 0.70, 0.80, 0.87, 1.03, and 1.70 mg/L, respectively, which increased significantly with disease stage (r = 0.53, P < 0.0001) as confirmed by Scheuer’s classification (r = 0.43, P < 0.0001). ATX correlated with Wisteria floribunda agglutinin-positive Mac-2 binding protein (M2BPGi) (r = 0.51, P < 0.0001) and fibrosis index based on four factors (FIB-4) index (r = 0.51, P < 0.0001). While ALP and M2BPGi levels had decreased significantly (both P < 0.001) by 12 months of ursodeoxycholic acid treatment, ATX had not (0.95 to 0.96 mg/L) (P = 0.07). We observed in a longitudinal study that ATX increased significantly (P < 0.00001) over 18 years in an independent group of 29 patients. Patients succumbing to disease-related death showed a significantly higher ATX increase rate (0.05 mg/L/year) than did survivors (0.02 mg/L/year) (P < 0.01). ATX therefore appears useful for assessing disease stage and prognosis in PBC.Satoru JoshitaTakeji UmemuraYoko UsamiYuki YamashitaGary L. NormanAyumi SugiuraTomoo YamazakiNaoyuki FujimoriTakefumi KimuraAkihiro MatsumotoKoji IgarashiKaname YoshizawaMasao OtaEiji TanakaNature PortfolioarticleMedicineRScienceQENScientific Reports, Vol 8, Iss 1, Pp 1-10 (2018) |
| institution |
DOAJ |
| collection |
DOAJ |
| language |
EN |
| topic |
Medicine R Science Q |
| spellingShingle |
Medicine R Science Q Satoru Joshita Takeji Umemura Yoko Usami Yuki Yamashita Gary L. Norman Ayumi Sugiura Tomoo Yamazaki Naoyuki Fujimori Takefumi Kimura Akihiro Matsumoto Koji Igarashi Kaname Yoshizawa Masao Ota Eiji Tanaka Serum Autotaxin Is a Useful Disease Progression Marker in Patients with Primary Biliary Cholangitis |
| description |
Abstract Autotaxin (ATX) is a secreted enzyme metabolized by liver sinusoidal endothelial cells that has been associated with liver fibrosis. We evaluated serum ATX values in 128 treatment-naïve, histologically assessed primary biliary cholangitis (PBC) patients and 80 healthy controls for comparisons of clinical parameters in a case-control study. The median ATX concentrations in controls and PBC patients of Nakanuma’s stage I, II, III, and IV were 0.70, 0.80, 0.87, 1.03, and 1.70 mg/L, respectively, which increased significantly with disease stage (r = 0.53, P < 0.0001) as confirmed by Scheuer’s classification (r = 0.43, P < 0.0001). ATX correlated with Wisteria floribunda agglutinin-positive Mac-2 binding protein (M2BPGi) (r = 0.51, P < 0.0001) and fibrosis index based on four factors (FIB-4) index (r = 0.51, P < 0.0001). While ALP and M2BPGi levels had decreased significantly (both P < 0.001) by 12 months of ursodeoxycholic acid treatment, ATX had not (0.95 to 0.96 mg/L) (P = 0.07). We observed in a longitudinal study that ATX increased significantly (P < 0.00001) over 18 years in an independent group of 29 patients. Patients succumbing to disease-related death showed a significantly higher ATX increase rate (0.05 mg/L/year) than did survivors (0.02 mg/L/year) (P < 0.01). ATX therefore appears useful for assessing disease stage and prognosis in PBC. |
| format |
article |
| author |
Satoru Joshita Takeji Umemura Yoko Usami Yuki Yamashita Gary L. Norman Ayumi Sugiura Tomoo Yamazaki Naoyuki Fujimori Takefumi Kimura Akihiro Matsumoto Koji Igarashi Kaname Yoshizawa Masao Ota Eiji Tanaka |
| author_facet |
Satoru Joshita Takeji Umemura Yoko Usami Yuki Yamashita Gary L. Norman Ayumi Sugiura Tomoo Yamazaki Naoyuki Fujimori Takefumi Kimura Akihiro Matsumoto Koji Igarashi Kaname Yoshizawa Masao Ota Eiji Tanaka |
| author_sort |
Satoru Joshita |
| title |
Serum Autotaxin Is a Useful Disease Progression Marker in Patients with Primary Biliary Cholangitis |
| title_short |
Serum Autotaxin Is a Useful Disease Progression Marker in Patients with Primary Biliary Cholangitis |
| title_full |
Serum Autotaxin Is a Useful Disease Progression Marker in Patients with Primary Biliary Cholangitis |
| title_fullStr |
Serum Autotaxin Is a Useful Disease Progression Marker in Patients with Primary Biliary Cholangitis |
| title_full_unstemmed |
Serum Autotaxin Is a Useful Disease Progression Marker in Patients with Primary Biliary Cholangitis |
| title_sort |
serum autotaxin is a useful disease progression marker in patients with primary biliary cholangitis |
| publisher |
Nature Portfolio |
| publishDate |
2018 |
| url |
https://doaj.org/article/715988f2566c47be81b9f75420628d74 |
| work_keys_str_mv |
AT satorujoshita serumautotaxinisausefuldiseaseprogressionmarkerinpatientswithprimarybiliarycholangitis AT takejiumemura serumautotaxinisausefuldiseaseprogressionmarkerinpatientswithprimarybiliarycholangitis AT yokousami serumautotaxinisausefuldiseaseprogressionmarkerinpatientswithprimarybiliarycholangitis AT yukiyamashita serumautotaxinisausefuldiseaseprogressionmarkerinpatientswithprimarybiliarycholangitis AT garylnorman serumautotaxinisausefuldiseaseprogressionmarkerinpatientswithprimarybiliarycholangitis AT ayumisugiura serumautotaxinisausefuldiseaseprogressionmarkerinpatientswithprimarybiliarycholangitis AT tomooyamazaki serumautotaxinisausefuldiseaseprogressionmarkerinpatientswithprimarybiliarycholangitis AT naoyukifujimori serumautotaxinisausefuldiseaseprogressionmarkerinpatientswithprimarybiliarycholangitis AT takefumikimura serumautotaxinisausefuldiseaseprogressionmarkerinpatientswithprimarybiliarycholangitis AT akihiromatsumoto serumautotaxinisausefuldiseaseprogressionmarkerinpatientswithprimarybiliarycholangitis AT kojiigarashi serumautotaxinisausefuldiseaseprogressionmarkerinpatientswithprimarybiliarycholangitis AT kanameyoshizawa serumautotaxinisausefuldiseaseprogressionmarkerinpatientswithprimarybiliarycholangitis AT masaoota serumautotaxinisausefuldiseaseprogressionmarkerinpatientswithprimarybiliarycholangitis AT eijitanaka serumautotaxinisausefuldiseaseprogressionmarkerinpatientswithprimarybiliarycholangitis |
| _version_ |
1718388193001209856 |